Drug intelligence / Profile preview

vehicle foam (Arcutis Biotherapeutics)

Development stage: Unknown
Lead developer: Arcutis Biotherapeutics, Inc.
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

Vehicle foam (Arcutis Biotherapeutics) is the inactive topical formulation used as the placebo control in clinical studies evaluating roflumilast foam (ZORYVE), such as the Phase 3 STRATUM trial for seborrheic dermatitis. It is designed to be identical in appearance and application to the active 0.3% roflumilast foam but lacks the active phosphodiesterase type 4 (PDE4) inhibitor. The use of this vehicle as a comparator allows researchers to isolate the therapeutic effects of the active drug from any potential moisturizing or barrier-repair effects provided by the foam base itself.

Other names: Vehicle

Beyond the preview

Go deeper on vehicle foam (Arcutis Biotherapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vehicle foam (Arcutis Biotherapeutics).

Explore the full profile